Scholarlink

<p>Recent evidence emphasizes the importance of arrhythmia burden as a&#xa0;key prognostic factor for patients with atrial fibrillation (AF). However, there are limited data on precise long-term determination of AF burden after catheter ablation (CA) by means of continuous ECG monitoring. In our retrospective cohort study, we analyzed 139 patients with symptomatic paroxysmal or persistent atrial fibrillation (AF) who were treated by CA and implanted with an implantable loop recorder (ILR) 1–3&#xa0;months before CA in our centre between 2011 to 2020. All patients underwent catheter pulmonary vein isolation by radiofrequency or cryobaloon ablation. In addition to quantification of AF burden, we sought to identify clinically relevant pre-ablation markers associated with the need of a redo procedure. We have shown a significant reduction of the mean AF burden with CA from 25.20% observed during the pre-ablation period to 1.43% during the first 6&#xa0;months post-ablation (<i>p</i> &lt; 0.001) and 2.05% (<i>p</i> &lt; 0.001) during the next 6&#xa0;months. It was accompanied by an important improvement of reported symptoms by at least 1 grade of EHRA symptom score in 78% of patients. Persistent AF and left atrial dilatation (diameter &gt; 49&#xa0;mm) were significant markers for the need for re-ablation (<i>p</i> &lt; 0.05). Our findings complement the growing pool of knowledge about this pivotal type of AF treatment with real-life long-term follow-up data on post ablation AF burden that are scarce in the published literature. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-Term Assessment of Atrial Fibrillation Burden After Catheter Ablation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Jihad Bou Ezzeddine,
  • Martin Svetlošák,
  • Peter Hlivák,
  • Marek Strachan,
  • Robert Hatala

摘要

Recent evidence emphasizes the importance of arrhythmia burden as a key prognostic factor for patients with atrial fibrillation (AF). However, there are limited data on precise long-term determination of AF burden after catheter ablation (CA) by means of continuous ECG monitoring. In our retrospective cohort study, we analyzed 139 patients with symptomatic paroxysmal or persistent atrial fibrillation (AF) who were treated by CA and implanted with an implantable loop recorder (ILR) 1–3 months before CA in our centre between 2011 to 2020. All patients underwent catheter pulmonary vein isolation by radiofrequency or cryobaloon ablation. In addition to quantification of AF burden, we sought to identify clinically relevant pre-ablation markers associated with the need of a redo procedure. We have shown a significant reduction of the mean AF burden with CA from 25.20% observed during the pre-ablation period to 1.43% during the first 6 months post-ablation (p < 0.001) and 2.05% (p < 0.001) during the next 6 months. It was accompanied by an important improvement of reported symptoms by at least 1 grade of EHRA symptom score in 78% of patients. Persistent AF and left atrial dilatation (diameter > 49 mm) were significant markers for the need for re-ablation (p < 0.05). Our findings complement the growing pool of knowledge about this pivotal type of AF treatment with real-life long-term follow-up data on post ablation AF burden that are scarce in the published literature.